Effects of Nafamostat mesilate on ADP-induced platelet aggregation and disaggregation in hemodialysis patients

ASAIO Journal

Volumn 52, Issue 3, 2006, Pages 272-275

  Miyata, Masahiro ^a   Shirakawa, Toshiro ^b   Acharya, Bishnu ^b   Terao, Shuji ^c   Gotoh, Akinobu ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b KOBE UNIVERSITY   (Japan)

^c KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMEDICAL ENGINEERING; HEMODIALYZERS; PATIENT TREATMENT; PLASMA FLOW;

EXTRACORPOREAL CIRCULATION (ECC); HEMODIALYSIS PATIENTS; NAFAMOSTAT MESILATE (NM); PLATELET AGGREGATION;

BLOOD VESSEL PROSTHESES;

ADENOSINE DIPHOSPHATE; NAFAMSTAT MESILATE; SODIUM CHLORIDE; ANTITHROMBOCYTIC AGENT; ENZYME INHIBITOR; GUANIDINE DERIVATIVE; NAFAMSTAT;

ADULT; ARTICLE; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HEMODIALYSIS; HUMAN; MALE; THROMBOCYTE AGGREGATION; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG EFFECT; EXTRACORPOREAL CIRCULATION; MIDDLE AGED; RENAL REPLACEMENT THERAPY;

ADENOSINE DIPHOSPHATE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; EXTRACORPOREAL CIRCULATION; FEMALE; GUANIDINES; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; RENAL DIALYSIS;

EID: 33746675664     PISSN: 10582916     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mat.0000209224.94089.bc     Document Type: Article

References (22)

1. Fujii S, Hitomi Y: New synthetic inhibitors of C1r, C1 esterase, thrombin, plasmin, kallikrein and trypsin. Biochim Biophys Acta 661: 342-35, 1981.
2. Hitomi Y, Ikari N, Fujii S: Inhibitory effect of a new synthetic protease inhibitor (FUT-175) on the coagulation system. Haemostasis 15: 164-168, 1985.
3. Uchiba M, Okajima K, Abe H, et al: Effect of nafamostat mesilate, a synthetic protease inhibitor, on tissue factor-factor VIIa complex activity. Thromb Res 74: 155-161, 1994.
4. Fuse I, Higuchi W, Toda K, Aizawa Y: Inhibitory mechanism of human platelet aggregation by nafamostat mesilate. Platelets 10: 212-218, 1999.
5. Lukaszyk A, Bodzenta-Lukaszyk A, Gabryelewicz A, Bielawiec M: Blood platelet function in canine acute pancreatitis with reference to treatment with nafamostat mesilate (FUT-175). Thromb Res 65: 229-39, 1992.
6. Imaizumi H, Kida M, Nishimaki H, et al: Efficacy of continuous regional arterial infusion of a protease inhibitor and antibiotic for severe acute pancreatitis in patients admitted to an intensive care unit. Pancreas 28: 369-73, 2004.
7. Takemoto Y, Tanaka S, Tanabe J, et al: Studies on the effects of primary therapy for DIC following circulatory arrest. Am J Hematol 21: 377-82, 1986.
8. Akizawa T, Koshikawa S, Ota K, et al: Nafamostat mesilate: A regional anticoagulant for hemodialysis in patients at high risk for bleeding. Nephron 64: 376-381, 1993.
9. Matsuo T, Kario K, Nakao K, et al: Anticoagulation with nafamostat mesilate, a synthetic protease inhibitor, in hemodialysis patients with a bleeding risk. Haemostasis 23: 135-141, 1993.
10. Hosokawa S, Oyamaguchi A, Yoshida O: Clinical evaluation of nafamstat mesilate (FUT 175): A new anticoagulant for plasmapheresis. ASAIO J 38: 59-60, 1992.
11. Kinugasa E, Akizawa T, Nakashima Y, et al: Nafamostat as anticoagulant for membrane plasmapheresis in high bleeding risk patients. Int J Artif Organs 15: 595-600, 1992.
12. Sundaram S, Gikakis N, Hack CE, et al: Nafamostat mesilate, a broad spectrum protease inhibitor, modulates platelet, neutrophil and contact activation in simulated extracorporeal circulation. Thromb Haemost 75: 76-82, 1996.
13. Usui A, Hiroura M, Kawamura M, et al: Nafamostat mesilate reduces blood-foreign surface reactions similar to biocompatible materials. Ann Thorac Surg 62: 1404-1411, 1996.
14. Mellgren K, Skogby M, Friberg LG, et al: The influence of a serine protease inhibitor, nafamostat mesilate, on plasma coagulation, and platelet activation during experimental extracorporeal life support (ECLS). Thromb Haemost 79: 342-347, 1998.
15. Kaminishi Y, Hiramatsu Y, Watanabe Y, et al: Effects of nafamostat mesilate and minimal-dose aprotinin on blood-foreign surface interactions in cardiopulmonary bypass. Ann Thorac Surg 77: 644-650, 2004.
16. Hodohara K, Fuziyama Y, Bamba T, Yasunaga K: Amidinonaphthol derivatives directly inhibit the ligand binding on platelet glycoprotein IIb-IIIa. Pathophysiology 2: 145-151, 1995.
17. Ozaki Y, Satoh K, Yamamoto T, et al: Detection of platelet aggregates with a particle counting method using light scattering. Anal Biochem 218: 284-94, 1994.
18. Gawaz MP, Dobos G, Spath M, et al: Impaired function of platelet membrane glycoprotein IIb-IIIa in end-stage renal disease. J Am Soc Nephrol 5: 36-46, 1994.
19. Cierniewski CS, Krzeslowska J, Pawlowska Z, et al: Palmitoylation of the glycoprotein IIb-IIIa complex in human blood platelets. J Biol Chem 264: 12158-12164, 1989.
20. Nurden P, Savi P, Heilmann E, et al: An inherited bleeding disorder linked to a defective interaction between ADP and its receptor on platelets. Its influence on glycoprotein IIb-IIIa complex function. J Clin Invest 95: 1612-1622, 1995.
21. Kawabata K, Nakai S, Miwa M, et al: Platelet GPIIb/IIIa is activated and platelet-leukocyte coaggregates formed in vivo during hemodialysis. Nephron 90: 391-400, 2002.
22. Kuragano T, Kuno T, Takahashi Y, et al: Comparison of the effects of cellulose triacetate and polysulfone membrane on GPIIb/IIIa and platelet activation. Blood Purif 21: 176-82, 2003.